Cargando…

Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent

INTRODUCTION: Coronary bifurcations are encountered in about 15% to 20% of percutaneous coronary interventions (PCIs). They are considered technically challenging and associated with worse clinical outcomes than nonbifurcation lesions. The BiOSS LIM C is a dedicated bifurcation balloon expandable st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil, Robert J., Pawłowski, Tomasz, Legutko, Jacek, Lesiak, Maciej, Witkowski, Adam, Gąsior, Mariusz, Kern, Adam, Bil, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455659/ https://www.ncbi.nlm.nih.gov/pubmed/30946377 http://dx.doi.org/10.1097/MD.0000000000015106

Ejemplares similares

Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
por: Gil, Robert J., et al.
Publicado: (2020)

Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry
por: Gil, Robert J., et al.
Publicado: (2020)

Comparative analysis of lumen enlargement mechanisms achieved with the bifurcation dedicated BiOSS(®) stent versus classical coronary stent implantations by means of provisional side branch stenting strategy: an intravascular ultrasound study
por: Gil, Robert J., et al.
Publicado: (2013)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Mehran in-stent restenosis classification adapted for coronary bifurcations: the impact on 4-year follow-up from randomized clinical studies POLBOS I and II
por: Bil, Jacek, et al.
Publicado: (2018)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Comparisons of the Effects of Stent Eccentricity on the Neointimal Hyperplasia between Sirolimus-Eluting Stent versus Paclitaxel-Eluting Stent
por: Kim, Byeong-Keuk, et al.
Publicado: (2010)

Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis
por: Bil, Jacek, et al.
Publicado: (2015)

Sirolimus-eluting coronary stents: a review
por: Abizaid, Alexandre
Publicado: (2007)

12-month intravascular ultrasound observations from BiOSS® first-in-man studies
por: Gil, Robert J., et al.
Publicado: (2016)

Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
por: Gasior, Pawel, et al.
Publicado: (2021)

Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
por: Kakizaki, Ryota, et al.
Publicado: (2020)

Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents
por: Sharma, Raghav, et al.
Publicado: (2022)

Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patients with acute myocardial infarction
por: Gąsior, Paweł, et al.
Publicado: (2018)

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents
por: Kim, J-S, et al.
Publicado: (2009)

Late Thrombosis of Sirolimus-Eluting Stent: A Multifactorial Problem
por: Kranjec, Igor, et al.
Publicado: (2009)

Long-term effectiveness and safety of sirolimus drug-eluting stents
por: Bikkina, Mahesh, et al.
Publicado: (2011)

Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent
por: Jakobsen, Lars, et al.
Publicado: (2022)

Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus drug-eluting stent
por: Podolec, Jakub, et al.
Publicado: (2019)

Comparison of drug-eluting and bare metal stents for extracranial vertebral artery stenting
por: Maciejewski, Damian R., et al.
Publicado: (2019)

Extensive Late-Acquired Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation
por: Choi, Hyun-Chul, et al.
Publicado: (2010)

48-Month Clinical Outcomes and Prognostic Factors in an All-Comers Population with Acute Coronary Syndrome and Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention with a Sirolimus-Eluting Stent
por: Tyczynski, Maciej, et al.
Publicado: (2023)

Elastic stent recoil in coronary total occlusions: Comparison of durable‐polymer zotarolimus eluting stent and ultrathin strut bioabsorbable‐polymer sirolimus eluting stent
por: Improta, Riccardo, et al.
Publicado: (2021)

Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up
por: Gil, Robert J., et al.
Publicado: (2017)

Treatment of a Coronary Bifurcation Lesion Using One Dedicated Sirolimus Eluting Bifurcation Stent in Combination with a Bioresorbable Vascular Scaffold: A Novel Option for Coronary Bifurcation Approach
por: Benezet, Javier, et al.
Publicado: (2016)

Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes
por: Zhang, Haijun, et al.
Publicado: (2016)

Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent
por: Jakobsen, Lars, et al.
Publicado: (2022)

A Case of Stent Thrombosis Occurred at 5 Years after Sirolimus-Eluting Stent Implantation
por: Kim, Su A, et al.
Publicado: (2011)

The different features of angiographic peri‐stent contrast staining after implantation of sirolimus‐eluting stents
por: Kageyama, Michiya, et al.
Publicado: (2017)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Reduction of In-Stent Restenosis and Inflammation with One Stent: New Concept of Sirolimus and Ascorbic Acid-Eluting Coronary Stent
por: Ryu, JiWung, et al.
Publicado: (2021)

Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry
por: Maeng, Michael, et al.
Publicado: (2012)

Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents
por: Iglesias, Juan F., et al.
Publicado: (2019)

Five-year clinical outcomes following drug-eluting stent implantation in left main trifurcations
por: Gil, Robert J., et al.
Publicado: (2019)

Long-term outcomes following drug-eluting balloon or thin-strut drug-eluting stents for treatment of in-stent restenosis stratified by duration of dual antiplatelet therapy (DEB-Dragon Registry)
por: Januszek, Rafał, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gbipd6clc349mmgm7itn6f53s0